drugset / Trial / NCT02273557
Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state with BID treatment
Timeline
- Start
- 2003-01
- Primary completion
- 2003-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dipyridamole | Other / unclassified | 200 mg | Oral |
| Background | ASA | Unknown | 25 mg | Oral |
Indications
No indication recorded.